The tender offer is fully financed, HSR-cleared, and recommended by the board with no competing bidder remaining. The key uncertainty is whether a sufficient number of shares (at least one share more than 50% of outstanding) will be tendered by the November 16 expiration. Monitor for any competing bid or shareholder appraisal demands.
Price Chart
Executive Summary
Pacira BioSciences' board unanimously recommends that shareholders tender their shares to Viatris' wholly owned subsidiary at $36.50 per share in cash, a ~45% premium over the undisturbed price. The recommendation follows a five-month process that included a market check of five potential strategic bidders (only one showed interest and later withdrew), a fairness opinion from Goldman Sachs, and the board's conclusion that the all-cash offer represents the best value reasonably obtainable given the risks of remaining standalone. The tender offer expires November 16, 2026, the HSR waiting period has expired, and the deal is not subject to a financing condition.
Key Financial Metrics
Key Facts
- Board unanimously recommends tender at $36.50/share cash, a ~45% premium over the $25.20 closing price on October 7, 2026
- Goldman Sachs rendered a fairness opinion that the $36.50/share is fair from a financial point of view
- Offer price was increased from Viatris' initial $31.00 proposal through active negotiation
- Five other potential strategic bidders were contacted; only one (Party A) entered discussions but withdrew on September 24, 2026
- HSR waiting period expired on October 29, 2026; no financing condition in the merger agreement
- Tender offer expires November 16, 2026; second-step merger under Section 251(h) of DGCL requires no shareholder vote
- Termination fee of $62.0 million if Pacira accepts a superior offer
- CEO Frank D. Lee would receive total golden parachute compensation of ~$30.1 million (including ~$24.3M in equity acceleration)
- Aggregate equity value of $1.65 billion based on 39,957,678 shares outstanding
- Activist investor DOMA Perpetual Capital fully exited its 2.94M share stake on October 8-13, 2026 at ~$36.29-$36.34/share
Financial Impact
All-cash acquisition of Pacira at $36.50/share, representing aggregate equity value of $1.65 billion and a ~45% premium to undisturbed price
Risk Factors
- Risk that insufficient shares are tendered to satisfy the Minimum Condition (more than 50% of outstanding shares)
- Shareholders may seek appraisal under Delaware law, potentially delaying or reducing consideration
- No competing bidder emerged despite market check; Party A withdrew citing concerns over EXPAREL patent litigation
- Activist investor DOMA fully exited at the offer price, reducing potential opposition but also indicating no higher bid expected
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 14D-9 Filing (Primary) | 0001140361-26-041229 |
| Document: ny20084560x1_exe26.htm | 0001140361-26-041229 |
| Document: ny20084560x1_exe27.htm | 0001140361-26-041229 |
| Document: ny20084560x1_exe28.htm | 0001140361-26-041229 |
| Document: 0001140361-26-041229-index-headers.html | 0001140361-26-041229 |
| Document: 0001140361-26-041229-index.html | 0001140361-26-041229 |
| Document: 0001140361-26-041229.txt | 0001140361-26-041229 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 30, 2026 2d ago | SC 13G/A | $36.40 | awaiting T+60 | awaiting T+60 | $36.39 (−0.03%) |
Oct 30, 2026 2d ago | SC 14D-9 | $36.39 | awaiting T+60 | awaiting T+60 | $36.39 (−0.00%) |
Oct 30, 2026 2d ago | SC TO-T | $36.39 | awaiting T+60 | awaiting T+60 | $36.39 (−0.00%) |
Oct 13, 2026 19d ago | SC 13D/A | $36.40 | awaiting T+60 | awaiting T+60 | $36.39 (+0.03%) |
Oct 8, 2026 24d ago | SC TO-C | $36.31 | awaiting T+60 | awaiting T+60 | $36.39 (+0.22%) |
Oct 8, 2026 24d ago | 144 | $36.39 | awaiting T+60 | awaiting T+60 | $36.39 (−0.00%) |
Oct 8, 2026 24d ago | 8-K | $36.39 | awaiting T+60 | awaiting T+60 | $36.39 (−0.00%) |
Oct 8, 2026 24d ago | SC TO-C | $36.39 | awaiting T+60 | awaiting T+60 | $36.39 (−0.00%) |
Aug 6, 2026 12w ago | Press Release | $25.58 $36.39 | ▲ +42.26% | ▲ +43.93% | $36.39 (+42.26%) |
Jul 22, 2026 14w ago | Press Release | $25.59 $36.33 | ▲ +41.97% | ▲ +38.71% | $36.39 (+42.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers